Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread
Completed
- Conditions
- Melanoma
- Registration Number
- NCT03165409
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
This study is a real-world retrospective claims analysis to assess and compare AE-related HCRU and medical costs among patients with different follow-up frequency after initiating a melanoma therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1828
Inclusion Criteria
- Diagnosed with metastatic melanoma
- Initiated at least 1 treatment for metastatic melanoma after 2011
- Continuous enrollment in their healthcare plan for at least 6 months before and at least 6 weeks after the index date
- Patients who received at least 1 dose of study drug in CA209-067
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment-related and all-cause AE costs for nivolumab/ipilimumab combination therapy for metastatic melanoma Approximately 5 years Treatment-related and all-cause AE costs for nivolumab monotherapy for metastatic melanoma Approximately 5 years Composite monthly incidence rate of adverse events (AEs), AE-related healthcare resource utilization, and medical costs among the metastatic melanoma patients with more frequent general outpatient visits Approximately 5 years Composite monthly incidence rate of adverse events (AEs), AE-related healthcare resource utilization, and medical costs among the metastatic melanoma patients with less frequent general outpatient visits Approximately 5 years Treatment-related and all-cause AE costs for ipilimumab monotherapy for metastatic melanoma Approximately 5 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Bristol-Myers Squibb
🇺🇸Princeton, New Jersey, United States